BenQ Medical Technology (4116) — Capital Reinvestment Ratio
BenQ Medical Technology (4116) has a Capital Reinvestment Ratio of 0.08x as of June 2025, meaning it reinvests 0% of its operating cash flow (NT$179.07 Million) in capital expenditures (NT$14.79 Million). Check 4116 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
BenQ Medical Technology Capital Reinvestment Ratio (2017–2024)
This chart tracks BenQ Medical Technology's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see BenQ Medical Technology cash conversion from operations.
Annual Capital Reinvestment Ratio for BenQ Medical Technology (2017–2024)
Year-by-year Capital Reinvestment Ratio for BenQ Medical Technology from 2017 to 2024. See 4116 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.79x | NT$222.22 Million | NT$175.48 Million | ▲ +150.8% |
| 2023 | 0.31x | NT$442.35 Million | NT$139.28 Million | ▲ +98.6% |
| 2022 | 0.16x | NT$378.77 Million | NT$60.05 Million | ▼ -41.6% |
| 2021 | 0.27x | NT$121.35 Million | NT$32.92 Million | ▼ -3.0% |
| 2020 | 0.28x | NT$151.48 Million | NT$42.37 Million | ▲ +123.8% |
| 2019 | 0.12x | NT$169.23 Million | NT$21.15 Million | ▼ -49.8% |
| 2018 | 0.25x | NT$126.10 Million | NT$31.36 Million | ▼ -83.8% |
| 2017 | 1.54x | NT$72.97 Million | NT$112.31 Million | — |